JNJ241220P160000
- 17.10
- +2.65+18.34%
Johnson & Johnson Newsroom
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow's Drop: How Blue-chips Have Fared During Index's Peak Turned Worst-run in Decades
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Least Shorted S&P 500 Stocks in November
Dow on a Record Losing Streak: Should You Buy Its ETF?
Express News | J&J: Application to EMA for New Indication Approval for Imbruvica in Adults With Previously Untreated Mcl Eligible for Autologous Stem Cell Transplant
Express News | U.S. FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's Stelara - Website
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $161
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab